| Clinical Presentation . | n = 46 . |
|---|---|
| Upper extremity lesions, No. (%) | 43 (93.5) |
| Redness, No. (%) | 28 (61) |
| Pain, No. (%) | 25 (54.3) |
| Abscess, No. (%) | 9 (19.6) |
| Skin manifestations,a No. (%) | 34 (74) |
| Lymphangitis, No. (%) | 12 (26.1) |
| Constitutional symptoms, No. (%) | 4 (8.7) |
| Symptom duration, median (IQR), d | 24 (9–246) |
| Laboratory findings | |
| WBC, mean ± SD, ×10(9)/L | 6.2 ± 2.2 |
| Platelets, median (IQR), ×10(9)/L | 243 (197–281) |
| Creatinine, mean ± SD, mg/dL | 1.08 ± 0.2 |
| ESR, median (IQR), mm/h | 5 (1.5–13.5) |
| CRP, median (IQR), mg/L | 3 (0.6–8.35) |
| Time of positive culture, median (IQR), wk | 3.5 (2.8–4.8) |
| Clinical Presentation . | n = 46 . |
|---|---|
| Upper extremity lesions, No. (%) | 43 (93.5) |
| Redness, No. (%) | 28 (61) |
| Pain, No. (%) | 25 (54.3) |
| Abscess, No. (%) | 9 (19.6) |
| Skin manifestations,a No. (%) | 34 (74) |
| Lymphangitis, No. (%) | 12 (26.1) |
| Constitutional symptoms, No. (%) | 4 (8.7) |
| Symptom duration, median (IQR), d | 24 (9–246) |
| Laboratory findings | |
| WBC, mean ± SD, ×10(9)/L | 6.2 ± 2.2 |
| Platelets, median (IQR), ×10(9)/L | 243 (197–281) |
| Creatinine, mean ± SD, mg/dL | 1.08 ± 0.2 |
| ESR, median (IQR), mm/h | 5 (1.5–13.5) |
| CRP, median (IQR), mg/L | 3 (0.6–8.35) |
| Time of positive culture, median (IQR), wk | 3.5 (2.8–4.8) |
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; WBC, white blood cell count.
aSkin manifestations include nodules, papules, and plaques.
| Clinical Presentation . | n = 46 . |
|---|---|
| Upper extremity lesions, No. (%) | 43 (93.5) |
| Redness, No. (%) | 28 (61) |
| Pain, No. (%) | 25 (54.3) |
| Abscess, No. (%) | 9 (19.6) |
| Skin manifestations,a No. (%) | 34 (74) |
| Lymphangitis, No. (%) | 12 (26.1) |
| Constitutional symptoms, No. (%) | 4 (8.7) |
| Symptom duration, median (IQR), d | 24 (9–246) |
| Laboratory findings | |
| WBC, mean ± SD, ×10(9)/L | 6.2 ± 2.2 |
| Platelets, median (IQR), ×10(9)/L | 243 (197–281) |
| Creatinine, mean ± SD, mg/dL | 1.08 ± 0.2 |
| ESR, median (IQR), mm/h | 5 (1.5–13.5) |
| CRP, median (IQR), mg/L | 3 (0.6–8.35) |
| Time of positive culture, median (IQR), wk | 3.5 (2.8–4.8) |
| Clinical Presentation . | n = 46 . |
|---|---|
| Upper extremity lesions, No. (%) | 43 (93.5) |
| Redness, No. (%) | 28 (61) |
| Pain, No. (%) | 25 (54.3) |
| Abscess, No. (%) | 9 (19.6) |
| Skin manifestations,a No. (%) | 34 (74) |
| Lymphangitis, No. (%) | 12 (26.1) |
| Constitutional symptoms, No. (%) | 4 (8.7) |
| Symptom duration, median (IQR), d | 24 (9–246) |
| Laboratory findings | |
| WBC, mean ± SD, ×10(9)/L | 6.2 ± 2.2 |
| Platelets, median (IQR), ×10(9)/L | 243 (197–281) |
| Creatinine, mean ± SD, mg/dL | 1.08 ± 0.2 |
| ESR, median (IQR), mm/h | 5 (1.5–13.5) |
| CRP, median (IQR), mg/L | 3 (0.6–8.35) |
| Time of positive culture, median (IQR), wk | 3.5 (2.8–4.8) |
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; WBC, white blood cell count.
aSkin manifestations include nodules, papules, and plaques.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
